Shuttle Pharmaceuticals Holdings, Inc. 8-K

What Happened

• Shuttle Pharmaceuticals Holdings, Inc. announced a board-approved one-for-ten (1:10) reverse stock split of its common stock, effective at the start of trading on June 11, 2026. The board approved the Reverse Stock Split on June 1, 2026 after stockholders authorized a reverse split ratio range (1:2 to 1:150) at the May 21, 2026 annual meeting. The company filed a Certificate of Amendment with the Delaware Secretary of State on June 10, 2026 (effective June 11).

Key Details

• Reverse split ratio: 1-for-10 (every 10 pre-split shares became 1 post-split share).
• Effective date/time: became effective at the start of trading on June 11, 2026.
• Convertible securities adjusted: outstanding warrants, restricted stock units and convertible preferred stock were proportionately reduced and their exercise/conversion prices were proportionately increased.
• No change to authorized shares; no fractional shares were issued — holders who would have received fractional shares instead received one full post-split share.
• New CUSIP for common stock: 825693500. VStock Transfer LLC is acting as exchange agent; holders in book-entry or “street name” need take no action. Trading on Nasdaq continues on a split-adjusted basis.

Why It Matters

• The reverse split reduces the number of outstanding shares and typically increases the per-share trading price (mathematically), while leaving the company’s market capitalization unchanged absent market reaction. Investors should note that convertible instruments and option/exercise prices were adjusted proportionately, and that the company did not change its total authorized share count. Check your brokerage account after the effective date for updated share totals and the new CUSIP.